Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca and QIAGEN enter collaboration to develop diagnostic test for lung cancer patients suitable for treatment with IRESSA

AstraZeneca today announced that it has entered into a collaboration
with Netherlands-based QIAGEN to develop a non-invasive diagnostic
test to identify non-small cell lung cancer (NSCLC) patients who are
suitable for treatment with IRESSA®.

IRESSA is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor that blocks the signals from the EGFR, which leads to
tumour growth. EGFR is a protein found in abnormally high levels on
the surface of many types of cancer cells, particularly non-small
cell lung cancer (NSCLC) cells. Using QIAGEN's diagnostic test,
doctors will be able to identify patients with the EGFR mutation, and
therefore who might benefit most from treatment with IRESSA, through
a blood test. Currently the main method of assessing EGFR mutation
status involves the collection of tumour tissue by needle biopsy or
during resection.

QIAGEN's test uses a highly sensitive assay to detect EGFR mutations
in the small fragments of circulating tumour DNA (ctDNA) in plasma
taken from patients' blood samples. The test has demonstrated robust
and reliable identification of EGFR mutation status using samples
from the Phase IV IRESSA Follow Up Measure (IFUM) study.

This collaboration is part of a long standing relationship between
AstraZeneca and QIAGEN. The two companies are seeking approval from
the European Medicines Agency for the ctDNA test, as a companion
diagnostic for IRESSA.

Mondher Mahjoubi, Senior Vice President, Global Product Strategy for
Oncology at AstraZeneca, said: "By combining AstraZeneca's expertise
in lung cancer with QIAGEN's diagnostic capabilities, we have the
potential to transform the way specific tumour types are identified
and treated. The use of circulating tumour DNA testing will allow
doctors to target the individual needs of each patient quickly and

"We are excited about this new partnership with AstraZeneca", said
Peer M. Schatz, CEO of QIAGEN. "Liquid biopsies are an exciting new
field in sample technology and an area of core leadership for QIAGEN.
We are rapidly expanding our portfolio in this field and are seeing a
broad uptake of our new standards. Our novel solutions for processing
tumor DNA and RNA from body fluids are being widely validated for
clinical use with existing and new assays and have the potential to
improve outcomes for patients for whom invasive surgery is not an




QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample & Assay Technologies that are used to
transform biological materials into valuable molecular information.
Sample technologies are used to isolate and process DNA, RNA and
proteins from biological samples such as blood or tissue. Assay
technologies are then used to make these isolated biomolecules
visible and ready for interpretation. QIAGEN markets more than 500
products around the world, selling both consumable kits and
automation systems to customers through four customer classes:
Molecular Diagnostics (human healthcare), Applied Testing (forensics,
veterinary testing and food safety), Pharma (pharmaceutical and
biotechnology companies) and Academia (life sciences research). As of
March 31, 2014, QIAGEN employed approximately 4,000 people in over 35
locations worldwide. Further information can be found at

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:


Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Vanessa Rhodes +44 20 7604 8037 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)

Jacob Lund +46 8 553 260 20 (Sweden)

Michele Meixell + 1 302 885 6351 (US)

Investor Enquiries

Karl Hård +44 20 7604 8123  mob: +44 7789 654364

Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729

Anthony Brown +44 20 7604 8067 mob: +44 7585 404943

Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.